Description
Indication & Scope
Endoxan® Cyclophosphamide for Injection provides chemotherapy of malignant lymphoma, various leukemia, breast cancer, ovarian cancer and other solid tumors; also applied for immunosuppressive therapy of severe autoimmune diseases.
- Mechanism: As an alkylating agent, it exerts cytotoxic effects by cross‑linking DNA strands to interfere DNA replication and transcription; it suppresses abnormal proliferation of tumor cells and over‑activated immune cells.
- Drug class: Alkylating antineoplastic agent, immunosuppressant.
- Clinical use: Administered in combined chemotherapy regimens for multiple malignancies; used for immune suppression in refractory severe autoimmune disorders.
| Generic Name | Cyclophosphamide for Injection |
| Brand Name | Endoxan® |
| Ingredient | Cyclophosphamide |
| Dosage Form | Injection |
| Package | 0.2g*1 vial/box;
1g*1 vial/box |
| Conditions Treated | Malignant lymphoma, leukemia, breast cancer, ovarian cancer, severe refractory autoimmune diseases |
| Taboos | Contraindicated in cases of severe bone marrow suppression, severe hepatic‑renal impairment, active severe infection, known hypersensitivity to cyclophosphamide or excipients, pregnancy and lactation period |
| Place of origin | Kantstr.2 33790 Halle, Germany |
| Prescription type | Prescription‑only |
| Storage Conditions | Store at controlled room temperature, protect from light, keep away from high‑humidity environment |
| Manufacturer | Baxter Oncology GmbH |
| Registration Authority | National Medical Products Administration (NMPA), China |
| Approval number | HJ20160467; HJ20160468 |
| Approval Date | Mar 14, 2026 |
| Shelf Life | 36 months |
How to use ?
Recommended Dose: Dosage is strictly weight‑based and disease‑oriented, determined by clinicians. Usual intravenous dose ranges from 500‑1000 mg per square meter of body surface area per treatment cycle.
Time: Administered under medical supervision during hospital chemotherapy cycles; timing adjusted according to chemotherapy protocols.
Instructions for use: Reconstitute with appropriate solvent before intravenous infusion. Only prepared and delivered by professional medical staff. Strict hematological monitoring is required throughout the treatment course.
Interaction: Enhanced myelosuppression when combined with other chemotherapeutic agents; interaction with barbiturates accelerates metabolic activation of cyclophosphamide; cardiac toxicity risk rises with anthracycline co‑administration.
Side effects:
1. Common adverse reactions include bone marrow suppression, alopecia, nausea and vomiting, hemorrhagic cystitis.
2. Severe reactions may comprise severe infection, hepatic function injury, reproductive system damage and secondary neoplasm risk.
Important Notice
This product should be administered only by qualified healthcare professionals in accordance with the approved prescribing information and local clinical guidelines. Dosage and administration may vary depending on patient condition, indicatiaon, and regional regulatory requirements.
Packaging & Shipping
Packaging
Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.
Shipping Methods
Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.
Export Support
Certificate of Analysis
GMP Certificate
Commercial Invoice
Packing List & CPP
Cold Chain Logistics
Customs Documentation
Scientific and regulatory sources
FAQ
What kinds of diseases can Cyclophosphamide for Injection be applied to treat?
It is used for multiple solid tumors and hematological malignancies, and can serve as immunosuppressant for severe autoimmune illnesses.
What main toxic risk needs close attention during administration of Cyclophosphamide for Injection?
Bone marrow suppression and hemorrhagic cystitis are major risks; regular blood test and clinical surveillance are mandatory.
Under what circumstances should Cyclophosphamide for Injection be forbidden for application?
Usage is forbidden for severe bone marrow suppression, active serious infection, known hypersensitivity, pregnancy and lactation status.
Can Cyclophosphamide for Injection be prepared and injected outside hospital setting?
No. Reconstitution and intravenous infusion must be completed by qualified medical personnel in medical institutions.
Endoxan® | Cyclophosphamide for Injection | Malignant Tumor | DengYueRX
INN: Cyclophosphamide for Injection
Indications: Malignant tumor
Dosage Form: Injection
Strength: 0.2g/vial
Original price was: $6.09.$5.17Current price is: $5.17.
